... WhatsApp

New Treatment Before and After Surgery Improves Bladder Cancer Survival

You are here >> Home > Latest Updates > Urinary Bladder Cancer > New Treatment…

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.DOI 10.1056NEJMoa2511674

Bladder cancer that grows into the muscle layer is serious. Many patients need surgery to remove the bladder. Some people cannot take standard chemotherapy. This makes treatment choices harder.

A new study tested a different approach. Patients received two medicines, enfortumab vedotin and pembrolizumab, before and after surgery. Doctors compared this with surgery alone.

The results showed a strong benefit. Patients who received the medicines had better outcomes. About 75% were free from cancer events after two years. In the surgery-only group, this number was much lower.

Survival also improved. More patients were alive after two years when they received the new treatment. Another key finding was tumor response. In many patients, no cancer was found at the time of surgery after treatment. This is a very positive sign.

What does this mean for patients?

If you cannot take standard chemotherapy, this new option may help. It can shrink the cancer before surgery and reduce the chance of it coming back later.

There are side effects. Some patients had serious reactions. This means careful monitoring is needed during treatment.

Still, the benefits are clear. Better survival and better cancer control give new hope.

If you have muscle-invasive bladder cancer, ask your doctor about treatment before surgery. New combinations like this are changing care and improving outcomes.

This study shows that adding modern therapies around surgery can make a big difference in survival.

Rate this post
dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.